Bli medlem
Bli medlem

Du är här

2016-11-09

FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Notes into shares

FIT Biotech Oy

Company release November 9, 2016 at 9:00 am EET

Conversion of FIT Biotech Oy's Convertible Notes into shares

Related to Convertible Note and Warrant Programmes established on September
26, 2016 between the Fit Biotech Oy ("Company") and Bracknor Investment
("Bracknor") the Company's board of directors has today resolved to approve
Bracknor's request relating to the funding programme to convert EUR 50,000
worth of Convertible Notes into the Company's K shares.

Due to the conversion of the Convertible Notes, the Company issues 494,315 new
K shares in the Company to Bracknor with the conversion price of EUR 0.10115
per share.

As a result of the issue of the new K shares in the Company, the total number
of shares in the Company will increase to 38,944,345 shares, and the share
capital of the Company will be increased by EUR 49,999.96. After the issue of
the new K shares in the Company, the Company's shares will be divided in
share series as follows: 38,873,881 K shares, 5,229 A shares and 65,235 D
shares.

The increase of the share capital and new K shares in the Company will be
registered in the Trade Register on or about November 10, 2016 and the new K
shares will be admitted to trading on First North Finland on or about
November 11, 2016.

FIT BIOTECH OY

Board of Directors

For further information:
Chairman of the Board of Directors Juha Vapaavuori
E-mail: juha.vapaavuori@fitbiotech.com
Tel: +358 50 372 0824

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company
develops and licenses its patented GTU® (Gene Transport Unit) vector
technology for new-generation medical treatments. GTU® is a gene transport
technology that meets an important medical challenge in the usability of gene
therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes.
Application areas include cancer (gene therapy) and infectious diseases such
as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace
maintained by Nasdaq Helsinki Oy.

DISTRIBUTION:
Nasdaq Helsinki
Principal media

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: FIT Biotech Oy via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.